You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-722-ESGO Phase 2 study assessing the efficacy of adding AL3818 (Catequentinib Dihydrochloride, Anlotinib Hydrochloride) to chemotherapies in subjects with platinum resistant ovarian carcinoma

Citation Tools

Article menu

Download PDFPDF

Ovarian cancer
2022-RA-722-ESGO Phase 2 study assessing the efficacy of adding AL3818 (Catequentinib Dihydrochloride, Anlotinib Hydrochloride) to chemotherapies in subjects with platinum resistant ovarian carcinoma
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Miller DS, Carlson M, Lea J, et al
2022-RA-722-ESGO Phase 2 study assessing the efficacy of adding AL3818 (Catequentinib Dihydrochloride, Anlotinib Hydrochloride) to chemotherapies in subjects with platinum resistant ovarian carcinoma
International Journal of Gynecologic Cancer 2022;32:A259.